David Band to Step Down from Pacific Edge Board

18 July 2018 David Band to Step Down from Pacific Edge Board Pacific Edge Limited (NZX:PEB) advises that long serving Director, David Band, has indicated that he will step down from the Board at the upcoming Annual Meeting, to be held in August 2018. David was appointed to the Board in 2007 and has held the position of Deputy Chair for most of his tenure. He has also been a member of a number of the Company's subsidiary Boards and advisory committees. Chair of Pacific Edge, Chris Gallaher, said: "David has made a significant contribution to Pacific Edge as the Company has developed its unique molecular diagnostic technology and embarked on its commercial journey. His experience in the life sciences sector, and expertise in corporate governance, talent management and commercialisation of innovation have been a key factor in Pacific Edge's successful evolution from R&D to commercial reality." David said: "It has been a privilege to have been able to contribute to the development and launch of Cxbladder, a diagnostic test that enables better care, better clinical decision making and better use of healthcare resources. As the Company moves ever close to commercial success, I believe it is now time to step down and allow for fresh thinking and skills to take the Company forward." Pacific Edge will take the opportunity to acknowledge David's contributions at the Annual Shareholders Meeting. The Board has a process underway to identify and appoint a new Director. ENDS For more information contact: David Darling Chief Executive Officer Pacific Edge Ltd P: +64 (3) 479 5800 OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies. ABOUT Cxbladder Triage www.cxbladder.com Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma. ABOUT Cxbladder Detect www.cxbladder.com Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy. ABOUT Cxbladder Monitor www.cxbladder.com Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer. ABOUT Cxbladder Resolve www.cxbladder.com Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings. Refer to www.cxbladder.com for more information. End CA:00320985 For:PEB Type:GENERAL Time:2018-07-18 09:00:08